Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Mar 2024 | From Akero Therapeutics

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study

Stephen A. Harrison, Juan P. Frias, K. Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, Yan Su, Doreen Chan, Erik J. Tillman, Ali Moulton, Brittany de Temple, Arian Zari, Reshma Shringarpure, Tim Rolph, Andrew Cheng, Kitty Yale Clinical Gastroenterology and Hepatology

Feb 2024 | From Akero Therapeutics

Decreases in liver cT1 accurately reflect histological improvement induced by therapies in MASH: a multi-centre pooled cohort analysis

Naim Alkhouri, Cayden Beyer, Elizabeth Shumbayawonda, Anneli Andersson, Kitty Yale, Timothy Rolph, Raymund Chung, Raj K Vuppalanchi, Kenneth Cusi, Rohit Loomba, Andrea Dennis, Michele Pansini medRxiv, the preprint server for Health Sciences

Nov 2023 | From Akero Therapeutics

Efruxifermin in Compensated Cirrhosis due to NASH/MASH: Results from a Randomized, Double-blind, Placebo-controlled, Phase 2b Trial (SYMMETRY)

Stephen A. Harrison The Liver Meeting 2023 (AASLD)

Nov 2023 | From Akero Therapeutics

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist (GLP-1RA) in Patients with NASH/MASH and T2D: a Randomized, Placebo-controlled Study (Cohort D)

Stephen A. Harrison, Juan P. Frias, K. Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, Yan Su, Doreen Chan, Erik J. Tillman, Ali Moulton, Brittany de Temple, Arian Zari, Reshma Shringarpure, Tim Rolph, Andrew Cheng, Kitty Yale The Liver Meeting 2023 (AASLD)

Oct 2023 | From Akero Therapeutics

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebocontrolled, phase 2b trial

Stephen A Harrison, Juan P Frias, Guy Neff, Gary A Abrams, K Jean Lucas, William Sanchez, Sudhanshu Gogia, Muhammed Y Sheikh, Cynthia Behling, Pierre Bedossa, Lan Shao, Doreen Chan, Erica Fong, Brittany de Temple, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale, for the HARMONY Study Group The Lancet Gastroenterology & Hepatology

Jun 2023 | From Akero Therapeutics

Noninvasive tests of liver injury, inflammation and fibrosis are improved by efruxifermin and correlate with histological improvements in patients with F2-F3 NASH: secondary analysis of Ph2b HARMONY study

Jörn M. Schattenberg, Juan Frias, Guy Neff, Gary A Abrams, Jeannie Lucas, William Sanchez, Sudhanshu Gogia, Muhammed Y. Sheikh, Cynthia Behling, Pierre Bedossa, Lan Shao, Erica Fong, Brittany de Temple, Doreen Chan, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale, and Stephen A Harrison 2023 International Liver Congress (EASL)

Jun 2023 | From Akero Therapeutics

Characterization of the Patterns of Resolution of Histopathology After Efruxifermin Treatment of Patients with NASH Fibrosis (F2/3) for 24 Weeks

Cynthia Behling, Pierre Bedossa, Lan Shao, Erica Fong, Brittany de Temple, Doreen Chan, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale, and Stephen A Harrison 2023 International Liver Congress (EASL)

Mar 2023 | From Akero Therapeutics

Efruxifermin, a long-acting, bivalent FGF21 analog, normalized noninvasive measures of liver injury, fibrosis, and metabolic health in patients with NASH and F2/F3 fibrosis over 24 weeks

Doreen Chan, Erik J Tillman, Reshma Shringarpure, Andrew Cheng, Stephen A Harrison, Kitty Yale, Tim Rolph Keystone Symposium: Metabolic and Molecular Mechanisms of NAFLD/NASH

We are evaluating potential treatments for MASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline

We are evaluating potential treatments for MASH and other serious metabolic diseases to build our pipeline.

View Our Pipeline